The Public Comment Period for Draft CMS FHIR® Digital Quality Measures (dQMs) is now open. Comment on Eligible Clinician dQMs, Hospital - Inpatient dQMs, and Hospital - Outpatient dQMs until February 23, 2026.
Top
Official websites use
.gov
A .gov website belongs to an official government organization in the United States.
Secure
.gov
websites use HTTPS
A
lock
(
)
or
https://
means you’ve safely connected to the
.gov
website. Share sensitive information only on official, secure websites.
["Adverse Event": "Thrombolytic medications"]
Performance/Reporting Period
2023
Value Set Description from VSAC
Clinical Focus: The purpose of this value set is to represent concepts for thrombolytic medications used for treatment of ST-segment elevation myocardial infaction (STEMI).
Data Element Scope: This value set may use a model element related to Medication.
Inclusion Criteria: Includes RXNORM codes that represent ingredients in thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions
Data Element Scope: This value set may use a model element related to Medication.
Inclusion Criteria: Includes RXNORM codes that represent ingredients in thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions
Constrained to codes in the Adverse Event: Thrombolytic medications value set (2.16.840.1.113762.1.4.1170.4)
QDM Datatype and Definition
"Adverse Event"
Data elements that meet criteria using this datatype should document the adverse event and its corresponding value set.
The relevant dateTime references the adverse event occurred.
The author dateTime references the time the adverse event was recorded.
eCQMs using this data element:
QDM Attributes
relevantDateTime
relevant dateTime addresses the time an activity occurs as a single point in time. If the activity occurs over a period of time, use relevantPeriod.
type
The characterization of the reaction (e.g., hypersensitivity, rash, gastroenteric symptoms, etc.).